Each ml suspension contains: 150 mg amoxycillin base (as trihydrate)
Spectrum of activity:
Amoxycillin is a broad spectrum, semi-synthetic penicillin with activity
against both Grampositive and Gramnegative bacteria. Sensitive are
streptococci, E. coli, Pasteurella spp., Proteus spp., Salmonella spp.,
Corynebacterium spp., staphylococci (β-lactamase negative),
The drug is destroyed by e.g. penicillinase-producing staphylocci.
Some Gramnegative strains are resistant against amoxycillin (R-plasmid). After intramuscular injection amoxycillin is quickly resorbed without irritation at the injection site.
Infections of the alimentary tract, respiratory tract, urogenital tract, coli-mastitis and secondary bacterial infections
during the course of viral diseases, in horses, cattle, pigs, sheep, dogs and cats.
New-borns, small herbivores (such as guinea pigs, rabbits), hypersensitivity to penicillins, renal dysfunctions,
infections caused by penicillinase-producing bacteria.
Amoxycillin is incompatible with fast-acting bacteriostatic antimicrobial drugs (e.g. tetracyclines, chloramphenicol,
Hypersensitivity reactions may occur, e.g. anaphylactic shock.
Dosage and administration:
The general dose is 15 mg/kg bodyweight i.m. (this is achieved by injection of 1 ml per 10 kg b.w.), daily during 3
In severe cases this dose may be given twice daily, (as there are no problems of toxicity).
Shake well before use.
For meat: 7 days.
For milk: 3 days.
Store between 8 ℃ and 15 ℃ and protected from light.
100 ml multidose vial.
FOR VETERINARY USE ONLY
Este vídeo versa sobre Proyecto sin título 2
Cancer Blueprint Day
The Keshe Foundation is proud to announce a new cancer solution breakthrough!
It is simple, inexpensive, and accessible to everyone.
Imagine there is a technology, which can not only balance your physical body, but also helps you finding out the roots of your own disease or the one of your patients! This technology, this knowledge is already available and as in every section of the Keshe Foundation, the knowledge is free for everyone, you can use it for yourself!
Nuclear Engineer Mehran Tavakoli Keshe will unveil for the first time to the public the new revolutionary cancer processing and clinical trial results by the use of new plasma technology in collaboration between the Keshe Foundation and Tokyo University Scientists.
Full clinical trial case with breast cancer will be presented by the doctors using this revolutionary processing.
Doctors, scientists, professionals, and press are invited to watch and participate in the presentation and examine the data presented.
Detailed information will be released on Tuesday April 18th, 2017 during the Cancer Blueprint Day, starting at:
09:00 AM CET Rome, IT
03:00 AM EDT New York, US
12:00 AM PDT Los Angeles, US
03:00 PM HKT Hong Kong, HK
05:00 PM AET Sydney, AU
Disclaimer: Every individual and company must take full responsibility for applying this new knowledge shared freely from the Keshe Foundation.
Simultaneous live streaming available at:
Zoom: https://spaceshipinstitute.zoom.us/j/939474503 (MIC POSSIBLE!)
Find more of our Public Teachings on Keshe plasma science and technology here: https://www.youtube.com/c/KeshefoundationOrg/playlists
Become a student at the world’s first Spaceship Institute! For only 100 euros, you get a full calendar year of access to live and recorded private teachings. There are thousands of hours of extended private teachings stored in our private portal at the Keshe Foundation Spaceship Institute (KF SSI).
Apply today to become a student at the KF SSI.
More information is available at our website https://kfssi.org
Direct link to Student Application Form is available at https://kfssi.org/study-apply